ConcertAI has transformed ASCO’s CancerLinQ into an AI-powered oncology platform delivering trial matching, clinical decision support, and real-world insights to close the care-research gap. More than a decade ago, the American Society of Clinical Oncology (ASCO) launched CancerLinQ , a platform designed to pool electronic health record data from oncology practices, turning routine patient encounters into a learning system. The platform has since become central to ConcertAI, an oncology-focused AI and real-world data company, which acquired it from ASCO in December 2023 . Before the acquisition, CancerLinQ’s most widely used function was automated reporting. “Before we bought it, CancerLinQ largely…
More than a decade ago, the American Society of Clinical Oncology (ASCO) launched CancerLinQ, a platform designed to pool electronic health record data from oncology practices, turning routine patient encounters into a learning system. The platform has since become central to ConcertAI, an oncology-focused AI and real-world data company, which acquired it from ASCO in…
The post How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform appeared first on Drug Discovery and Development.
US Pharma Marketing